HONG KONG – China has approved its third homegrown PD-1 drug in merely six months, with a nod for camrelizumab, developed by pharma R&D giant Jiangsu Hengrui Medicine Co. Ltd., as a third-line treatment for recurrent or refractory classical Hodgkin lymphoma.